Johnson & Johnson (JNJ)

Investors worried about market turmoil may want to look at reliable dividend stocks, and these five stand out.

Eli Lilly's sales jumped 44.7% last year, while Johnson & Johnson's steadier profile raises a different question for cautious portfolios.

The business has undergone major changes in recent years, and these might pay off over the medium term.

AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology

Keep focusing on the long term.

Value stocks are crushing growth stocks as investors sour on the artificial intelligence trade.

The stock market is looking overvalued, according to this indicator.

Some companies will perform pretty well regardless of whether or not interest rates rise.

They have both outperformed the broader equity market over the long run.

This ETF offers a smart middle ground for investors anxious about the AI trade but who don't want to sit on the sidelines.

AbbVie, J&J, and Medtronic remain reliable dividend plays in a rough market.

Selling surgical robots is not the largest source of Intuitive Surgical's revenue.

Medtronic grew revenue by 14% in the first quarter of its fiscal 2027.

Consumers don't stop buying vital products during bear markets, which is why healthcare and consumer staples stocks are smart investments.

Johnson & Johnson's third-quarter 2026 earnings look terrible, until you dig into the story a little bit more.

Instead of trying to pick stocks like Warren Buffett, follow his advice and buy this S&P 500 ETF.

With just two days to go, these Dividend Kings with attractive yields could be just what you are looking for in October.

Teradyne, Grail, Kratos Defense, FormFactor and Fabrinet have pulled back despite strong growth, setting up potential entry points in robotics, quantum and AI.

Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.

Intuitive Surgical posted Q3 margin impairments from a legal settlement and pricing changes, but revenue grew 21.5%, guidance firmed, and analysts and institutions remain bullish on ISRG.

The market has rewarded this biotech for its breakthroughs.

These drugmakers are facing some near-term challenges, but is that enough to stop their recent momentum?